5-Aminolevulinic acid hydrochloride (5-ALA HCl), CAS 5451-09-2, molecular formula C5H9NO3·HCl, molecular weight 167.59 g/mol, is supplied as a white to off-white crystalline active pharmaceutical ingredient for tablet, capsule, granule, oral solution, and injectable dosage forms. The product code ALA-HCl-PG-01 identifies a direct-compression and granulation grade with controlled particle size; ALA-HCl-PG-02 identifies a low-endotoxin, low-bioburden grade intended for aseptic solution filling. The molecule acts as a metabolic prodrug: mitochondrial condensation with glycine followed by heme-pathway enzymes generates protoporphyrin IX (PpIX), the actual fluorophore and photosensitizer, rather than administering a preformed tetrapyrrole. This distinction avoids the slow tissue clearance associated with some preformed porphyrin APIs and allows the finished product to be used in photodynamic diagnosis and photodynamic therapy under controlled light exposure. The hydrochloride salt, not the free base, is selected because the protonated amino group yields a defined crystalline lattice that is less hygroscopic than the free base and because aqueous solubility is sufficiently high for rapid dissolution in oral solid dosage forms and for preparation of concentrated aseptic solutions.

Why is the hydrochloride salt specified for oral and injectable dosage forms?

5-ALA free base is difficult to mill and chemically reactive toward self-condensation; the hydrochloride form converts the primary amino group into the protonated ammonium state, which stabilizes the δ-amino ketone against intramolecular aminal formation and reduces oxidative discoloration. The crystalline solid is typically delumped through a 500 µm stainless-steel screen before blending. Dry milling is preferred over micronization because the substance is water-soluble and high-energy micronization can increase amorphous content, causing particle agglomeration at relative humidity above 60%. The salt also produces an acidic aqueous solution; pH is measured by Ph. Eur. 2.2.3 or USP <791>, and the acceptance criterion is set in the finished product dossier because concentrated solutions can alter the pH of the blend granulation liquid. In tablet and capsule manufacture, the salt is dispensed by weight after loss on drying correction, and excipients are selected for compatibility with the acidic API surface.

The freely water-soluble nature of 5-ALA HCl means dissolution failure is rarely caused by the API itself. Content uniformity and segregation under high-speed tableting are more critical. In a production-scale rotary tablet press, a direct-compression blend requires external lubrication with magnesium stearate at 0.5–1.0 wt% and controlled relative humidity because the API can adsorb moisture and increase particle cohesion. Capsule blends are dry-filled on a dosator or tamping-pin machine; fill weight is adjusted by tapped density and flow ratio. The API is not intrinsically a direct-compression binder, so the formulation must supply compactability and flow control. Published data for this specific configuration is limited; process ranges are typically established as bracket studies within individual marketing authorizations.

Release specifications, residual solvent control, and elemental impurity screening

The API release panel includes identification by infrared absorption and HPLC retention time, chloride test, assay on dried basis, related substances, loss on drying, residual solvents, elemental impurities, microbial enumeration, and bacterial endotoxins for the parenteral grade. The values in Table 1 align with Ph. Eur. and USP general chapters but should be verified against the active dossier because compendial monographs may not list all product codes.

Density, flow, and compressibility are not compendial identity tests but are routinely measured for solid oral processing. Bulk density of a crystallized milled batch is often controlled between 0.35 g/mL and 0.55 g/mL; tap density is measured by USP <616> method 1. Flow through a 10 mm stainless-steel funnel may require glidant addition because cohesive fines from milling can form stable bridges in the hopper. The material is not hygroscopic in the manner of sodium valproate, but moisture-induced agglomeration is observed above 60% RH; bulk packaging therefore uses desiccant-lined aluminium pouches inside HDPE drums.

For tablet and capsule manufacture, 5-ALA HCl is dry-blended with direct-compression excipients. Aqueous wet granulation is generally avoided because the binder solution rapidly dissolves the API and can produce dried granules with high breaking strength and non-uniform drug distribution. When granulation is required, a roller compactor with smooth rolls at 5–12 kN/cm linear force is used, followed by screening through a 1.0 mm oscillating granulator. The resulting granule fraction is blended with extragranular disintegrant and lubricant. Tablet hardness for a 200 mg core is often set in the range of 70–100 N, but the exact compression profile is determined by the final formulation because the API itself is not a direct-compression binder.

Oral granules for sachet or pediatric administration are prepared either by coating sugar spheres with 5-ALA HCl and a polymeric binder or by spraying the API solution onto dry carriers in a fluid-bed coater. The top-spray process is limited by the high water solubility of the API; if the spray rate exceeds the evaporation capacity, the bed collapses and the nozzle becomes obstructed. A production-scale Wurster insert with a 18-inch bowl and 1.0 mm nozzle is often operated at product temperature 28–32 °C and inlet air dew point below 10 °C to keep the bed free-flowing. Equipment manufacturer technical bulletins recommend delta-P and filter-shaker intervals to prevent binder accumulation on the bag filter when the API solution is highly concentrated.

When the route is changed from oral capsule filling to aseptic injection, which attributes dominate?

Parenteral-grade 5-ALA HCl requires a tighter bacterial endotoxin specification because the limit must be derived from the maximum bolus dose and the endotoxin limit for the finished injection described in Ph. Eur. 2.6.14 or USP <85>. Subvisible particulate matter becomes critical after dissolution or reconstitution; the finished injected solution is controlled by Ph. Eur. 2.9.19 and USP <788> for particles ≥10 µm and 25 µm. The API is typically dissolved in Water for Injections at 15–25 °C and passed through a 0.22 µm polyethersulfone filter in an aseptic isolator because the δ-amino ketone can undergo heat-accelerated dimerization. pH adjustment is performed with dilute hydrochloric acid or sodium hydroxide under nitrogen purge to limit oxidative degradation. Terminal steam sterilization is generally avoided unless degradation kinetic data support the specific time–temperature cycle.

For injectable products, the API release panel adds single-point and cumulative subvisible particulate limits, higher bioburden control, and stricter residual moisture if the material is lyophilized. If 5-ALA HCl is filled as a solution, the holding time between dissolution and filtration is limited by in-process data; the solution is protected from light at 400–700 nm and held at controlled temperature to avoid pre-PpIX formation before administration. The finished injection is packaged in amber glass vials under nitrogen headspace, and leachable studies follow Ph. Eur. 3.2.1 and USP <1660> or applicable compendial general chapters for elastomeric closure systems.

Compared with aminolevulinic acid methyl ester or hexyl ester, the HCl salt of 5-ALA is the parent acid, not an esterified prodrug. Ester derivatives are used in topical formulations because of higher lipophilicity; the HCl salt is preferred for oral and injectable solutions because it is freely water-soluble and does not require esterase-mediated hydrolysis. Table 2 summarizes operational differences between the hydrochloride salt and preformed photosensitizer APIs.

For solid oral development, 5-ALA HCl differs from many low-solubility APIs because it does not require nanosizing or amorphous solid dispersion to achieve rapid dissolution. Its high solubility shifts the formulation challenge toward physical stability of the blend, segregation control, and moisture management. For parenteral development, the challenge shifts toward chemical degradation kinetics, endotoxin control, and compatibility with primary packaging. The API is not interchangeable with the free base, the methyl ester, or preformed porphyrin APIs without reformulation and separate stability data.

Bulk storage of 5-ALA HCl follows ICH Q1A(R2) conditions for long-term and accelerated stability evaluation. The substance is stored in tightly closed containers protected from light and moisture. If the warehouse dew point exceeds +10 °C, active desiccant is required in the bulk container because repeated partial opening can introduce humid air and promote surface discoloration. Handling areas are maintained at 18–22 °C and 45–55% RH; operators wear nitrile gloves and dust extraction is used during dispensing to limit occupational exposure to the active substance.